Bengaluru: The U.S. health regulator’s staff on Wednesday flagged concerns that data on Merck’s chronic cough drug might not be enough to prove the treatment’s meaningful benefit, documents released ahead of a meeting of independent experts showed. Shares of the drugmaker were down nearly 1 per cent at $101.2 in afternoon trade. The concerns were … Read more
Key Points The Health Care Select Sector SPDR Fund has dropped 3.81% in the last month and 8.03% in the past three months. Pharmaceuticals’ weak earnings reports are contributing to the healthcare sector’s recent underperformance. Bristol Myers Squibb, AbbVie, Merck, Johnson & Johnson, and Pfizer all traded below previous highs due to earnings concerns. 5 … Read more
Following is a summary of current health news briefs. More bumps in the road to wiping out polio – report The global effort to end polio is likely to miss two key targets this year on the path towards defeating the virus, according to an independent strategic review. The aim in 2023 was to interrupt … Read more
Illustration by Lynne Carty/Barron’s staff; Dreamstime (4) Medicine is making big gains in the battle against cancer, enlisting the body’s own immune system to control or eliminate previously deadly tumors with a host… Source link credite
Merck Animal Health, affiliated to drug major Merck & Co., Inc., has recalled three batches of Banamine/Banamine-S (flunixin meglumine injection) 50 mg/mL in the United States citing the presence of particulate matter. Flunixin meglumine is a potent, non-narcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. The U.S. Food and Drug Administration noted that the … Read more